X
X
Total 393357 Results
| Label | Description | ILX | Version | Created CID | Modified Time | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dromostanolone | Dromostanolone is a potent synthetic androgenic anabolic steroid similar to testosterone. Dromostanolone is indicated in postmenopausal women with recurrent breast cancer, in a combined hormone therapy. Pharmacology: Dromostanolone is a synthetic androgen, or male hormone, similar to testosterone. Dromostanolone works by attaching itself to androgen receptors; this causes it to interact with the parts of the cell involved in the making of proteins. It may cause an increase in the synthesis of some proteins or a decrease in the synthesis of others. These proteins have a variety of effects, including blocking the growth of some types of breast cancer cells, stimulating cells that cause male sexual characteristics, and stimulating the production of red blood cells. Mechanism of action: Dromostanolone is a synthetic androgenic anabolic steroid and is approximately 5 times as potent as natural methyltestosterone. Like testosterone and other androgenic hormones, dromostanolone binds to the androgen receptor. It produces retention of nitrogen, potassium, and phosphorus; increases protein anabolism; and decreases amino acid catabolism. The antitumour activity of dromostanolone appears related to reduction or competitive inhibition of prolactin receptors or estrogen receptors or production. Drug type: Approved. Illicit. Small Molecule. Drug category: Anabolic Agents. Antineoplastic Agents, Hormonal | ILX:0103562 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Drooping | To bent or hang downwards. | ILX:0103563 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Drop-Dead Mutant Drosophila | The Drop-Dead Mutant Drosophila carries an X-chromosomal recessive mutation that causes severe behavioral defects and brain degeneration, manifested a few days after emergence of the adult. This mutation causes age related neurodegeneration and locomoter dysfunction and these mutants typically have very abbreviated life spans. Some common effects of this mutation are a slightly bent wing margin, frequent hypertrophy of the abdomen, reduced body size, recessive sterility in homozygous mutant females, and brain lesions. These mutants are used to study Parkinson's Disease in some laboratories. | ILX:0103564 | 4 | scicrunch | 08/24/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Droperidol | A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as an antiemetic, and for the control of agitation in acute psychoses. (From Martindale, The Extra Pharmacopoeia, 29th ed, p593) Pharmacology: Droperidol produces marked tranquilization and sedation. It allays apprehension and provides a state of mental detachment and indifference while maintaining a state of reflex alertness. Droperidol produces an antiemetic effect as evidenced by the antagonism of apomorphine in dogs. It lowers the incidence of nausea and vomiting during surgical procedures and provides antiemetic protection in the postoperative period. Droperidol potentiates other CNS depressants. It produces mild alpha-adrenergic blockade, peripheral vascular dilatation and reduction of the pressor effect of epinephrine. It can produce hypotension and decreased peripheral vascular resistance and may decrease pulmonary arterial pressure (particularly if it is abnormally high). It may reduce the incidence of epinephrine-induced arrhythmias, but it does not prevent other cardiac arrhythmias. Mechanism of action: The exact mechanism of action is unknown, however, droperidol causes a CNS depression at subcortical levels of the brain, midbrain, and brainstem reticular formation, may antagonize the actions of glutamic acid within the extrapyramidal system, may inhibit cathecolamine receptors and the reuptake of neurotransmiters, has strong central antidopaminergic action and weak central anticholinergic action, produces ganglionic blockade and reduces affective response. Drug type: Approved. Small Molecule. Drug category: Adjuvants, Anesthesia. Antiemetics. Antipsychotic Agents. Dopamine Antagonists | ILX:0103565 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Drosophila | a genus of small flies, belonging to the family Drosophilidae, whose members are often called fruit flies"" | ILX:0103566 | 6 | scicrunch | 08/24/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Drosophila melanogaster | ILX:0103567 | 5 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Drosophila overexpressing Gprk2 | This transgenic Drosophila coexpresses alpha-synuclein and G protein-coupled recepter kinase (Gprk2). Overexpression of Gprk2 increases phosphorylation at Ser129 and enhances alpha-synuclein toxicity. | ILX:0103568 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Drosophilidae | ILX:0103569 | 5 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Drosophilina | ILX:0103570 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Drosophilinae | ILX:0103571 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Drosophilini | ILX:0103572 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Drosophiliti | ILX:0103573 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Drospirenone | Drospirenone is a synthetic progestin that is an analog to spironolactone. It is found in a number of birth control formulations. Drospirenone differs from other synthetic progestins in that its pharmacological profile in preclinical studies shows it to be closer to the natural progesterone. As such it has anti-mineralocorticoid properties, counteracts the estrogen-stimulated activity of the renin-angiotensin-aldosterone system, and is not androgenic. Pharmacology: Drospirenone differs from other synthetic progestins in that its pharmacological profile in preclinical studies shows it to be closer to the natural progesterone. As such it has anti-mineralocorticoid properties, counteracts the estrogen-stimulated activity of the renin-angiotensin-aldosterone system, and is not androgenic. Mechanism of action: Progestins such as drospirenone diffuse freely into target cells in the female reproductive tract, mammary gland, hypothalamus, and the pituitary and bind to the progesterone receptor. Once bound to the receptor, progestins slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH surge. Drug type: Approved. Small Molecule. Drug category: Aldosterone Antagonists | ILX:0103574 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Drotrecogin alfa | Human Protein C that has been enzymatically activated by cleavage with thrombin and subsequently purified. Drotrecogin alfa (activated) is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Pharmacology: Activated Protein C exerts an antithrombotic effect by inhibiting (cleaving) Factors Va and VIIIa. In vitro data indicate that Activated Protein C has indirect profibrinolytic activity through its ability to inhibit plasminogen activator inhibitor-1 (PAI-1) and limiting generation of activated thrombin-activatable-fibrinolysis-inhibitor. The net effect is the reduction or elimination of blood clots Mechanism of action: Activated protein C combines with protein S on platelet surfaces and then degrades factor Va and factor VIIIa. Drug type: Approved. Biotech. Investigational. Drug category: Antisepsis Agents | ILX:0103575 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Drug | Any substance which when absorbed into a living organism may modify one or more of its functions. The term is generally accepted for a substance taken for a therapeutic purpose, but is also commonly used for abused substances. | ILX:0103576 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Drug administration paradigm | A paradigm in which a drug is administered to a subject through a specific route of administration, over an interval of time and/or at specific intervals, e.g., chronic cocaine paradigm | ILX:0103577 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Drug of abuse role | A drug that is taken for nonmedicinal reasons (usually for mind-altering effects) (Wordnet) | ILX:0103578 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Drug withdrawal paradigm | An experimental paradigm where the subject is withdrawn from a drug or other compound | ILX:0103579 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dry | UA wetness quality inhering in a bearer by virtue of not being covered by a liquid. | ILX:0103580 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dry senile macular retinal degeneration | ILX:0103581 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
About
Base community for the SciCrunch.org infrastructure
Contact Us
X